Current state · 2026.
The 2026 picture is a five-regulator divergence matrix overlaid with a partially harmonised E6(R3) substrate. The shifts below are operational, not theoretical — they affect dossier preparation today.
Current state, 2026.
What is live nowThe 2026 picture is a five-regulator divergence matrix overlaid with a partially harmonised E6(R3) substrate. The shifts below are operational, not theoretical — they affect dossier preparation today.
Step 4 reached, implementation rolling.
FDA draft guidance 2025, final late 2026. EMA adopted 2025. MHRA aligned. PMDA GCP Ordinance amendment 2026–2027. CDSCO still primarily R2. ANVISA RDC 945 high-alignment with R3 spirit.
Transition window closed.
All ongoing EU trials under CTR 536/2014 from 31 Jan 2025. Single submission, Reporting MS / Concerned MS dynamics stabilising. Public disclosure (protocols, lay summaries, results) default with limited deferral. Midcap and academic sponsors under-resourced.
Divergence persists.
FDA (21 CFR 50/56/312) · EMA (CTR 536/2014, CTIS) · CDSCO (NDCT 2019, 30/90-day) · PMDA (GCP Ordinance, pre-consultation heavy) · ANVISA (RDC 945/2024, 90/180-day, VICTOR).
FDA most predictable.
FDA IND 30-day safe-to-proceed (reliable). EMA CTR Part I 45 days + 31+31 (CTIS validation adds 10–25 days). CDSCO 30 working days (SEC bottleneck). PMDA 30 days post-CTN. ANVISA 90/180 working days (variance high).
Regulatory option, not experimental.
FDA final DCT guidance 2024. EMA 2022 recommendation paper updated 2024. MHRA combined-review DCT-friendly. Health Canada explicit 2024. PMDA cautious. CDSCO less codified. ANVISA RDC 945 recognises DCT elements.
Operational standard.
FDA FDORA Section 3602 draft guidance June 2024 now operational for Phase 3/pivotal drug-device trials. Enrolment goals (race, ethnicity, sex, age) plus rationale and operational measures. Q1 2026 first full-cycle data. Rare-disease sponsors flag feasibility.
MDR Article 117 in force.
FDA 21 CFR 4 + PMOA-led IND or IND+IDE. EU: CTR medicinal portion + MDR Article 117 notified-body opinion for device-integral DDCs. CDSCO recognised but determination less codified. PMDA Combination Office. ANVISA RDC 751 + RDC 945 case-by-case.
Brazil most attractive LATAM CT jurisdiction.
Statutory 90/180 working-day timelines holding. VICTOR single-window operational. CONEP/CEP integration improved. DCT recognition welcomed. Combination-product RDC 945 + RDC 751 requires sponsor coordination.
CDSCO Observer → Member.
NDCT 2019 codifies modern framework. E6(R2) substantially implemented. E6(R3) alignment in progress. Q-series mature. PvPI expanding. Industry expectation: 2027–2029 full ICH Regulatory Member status conditional on inspection capacity.
Single-IRB now common in US.
FDA local + central IRB permitted. EMA Part II national (1 vs. multiple EC per MS varies). CDSCO central + IEC registered, mandatory re-registration. PMDA per-site IRB with central pilots. ANVISA CONEP federal + CEP local.
Frontier remains open.
Synthetic control arms in pivotals (case-by-case). AI/ML adaptive designs (ICH E20 traditional framework, AI-specific limited). In-silico trial evidence (mechanistic/device niche). Continuous submission models (pilot). Genomic-stratified ultra-rare (immature).
Friction, not convergence.
GDPR (EU), DPDP (India), LGPD (Brazil), HIPAA (US). DCT direct-to-participant IMP and telemedicine intersect three or four regimes per trial. Source-data verification across jurisdictions remains an inspection question.
Design-agnostic baseline.
WHO Good Clinical Trials Practice 2024 frames quality without prescribing design. Useful for LMIC regulators bootstrapping frameworks. Listed Authority pathway parallel-tracks regulator maturity.